|
|
|
Baxter International Inc (NYSE: BAX) |
|
|
|
| |
Baxter International Inc Outlook |
On February 20 2025 the Baxter International Inc provided following guidance
nnBaxter International Inc. Reports Financial Results for Q4 and Full Year 2024, Outlines 2025 Guidancenn
nnDEERFIELD, Ill. ? February 20, 2025nn ? Baxter International Inc. (NYSE: BAX), a renowned leader in the global medtech industry, has today announced its financial results for the fourth quarter and the entire year ended December 31, 2024. In conjunction with these results, the company has also provided its financial guidance for the first quarter and the full fiscal year 2025.
Brent Shafer, the chair and interim chief executive officer of Baxter, commented on the company?s performance, stating, Our results from 2024 and the strategic milestones we achieved underscore Baxter's growing momentum as we strive to deliver increased value for patients, healthcare providers, customers, and shareholders alike.
While specific figures and projections related to the financial guidance for 2025 were not disclosed in the announcement, the company remains focused on executing its strategic initiatives aimed at driving growth and innovation in the medtech sector.
Baxter?s leadership is optimistic about the future as they continue to enhance their product offerings and expand their market reach. The financial outlook for the upcoming year implies a commitment to advancing the company?s objectives while remaining responsive to the evolving needs of the healthcare landscape.
For more detailed insights and figures regarding Baxter's performance in 2024 and further information about the guidance for 2025, applicable stakeholders and s are encouraged to stay tuned for additional communications from the company.,
|
On February 8 2024 the Baxter International Inc provided following guidance
division, and the acquisition of several key assets.
For the fourth quarter of 2023, Baxter reported net sales of $4.5 billion, an increase of 8% compared to the same period in the previous year. This growth was driven by strong performance across all of our business segments, particularly in our Renal Care and Medication Delivery segments. Adjusted earnings per share for the quarter were $0.97, a 12% increase compared to the fourth quarter of 2022.
For the full year 2023, Baxter reported net sales of $16.8 billion, a 7% increase compared to the previous year. This growth was driven by strong demand for our renal care products, medication delivery systems, and pharmaceuticals. Adjusted earnings per share for the full year were $3.79, a 9% increase compared to the previous year.
Looking ahead to full-year 2024, Baxter expects net sales to be in the range of $17.5 billion to $18 billion, representing a growth of approximately 4% to 7% compared to 2023. This growth is expected to be driven by continued strong demand for our renal care products and medication delivery systems, as well as the launch of several new products across our portfolio.
Baxter also provided its financial guidance for the first quarter of 2024, expecting net sales to be in the range of $4.2 billion to $4.4 billion, representing a growth of approximately 4% to 9% compared to the first quarter of 2023. Adjusted earnings per share for the first quarter are expected to be in the range of $0.90 to $0.95.
In summary, Baxter International Inc. delivered strong financial results in 2023, driven by strategic initiatives and strong demand for its products. The company expects to continue this momentum in 2024, with projected sales growth and the launch of new products contributing to its future success.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
